Fairvalue-Calculator Fairvalue-Calculator
EN DE

Alvotech, through its subsidiaries, (ALVO) Fair Value & Analysis

Healthcare · US · Market cap $1.2B

Price$3.70
Fair Value$1.52
Upside-58.9%
Quality95/100
Evidence: Medium Range $1.48 – $1.90

Fair value as of: Jun 24, 2026

Analysis

Alvotech, through its subsidiaries, (ALVO) currently trades at $3.70, while our model-based Fair Value estimate is $1.52 — implying the stock looks roughly 58.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, …

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% Divi's Laboratories Limited (DIVISLAB) -78%

Frequently asked questions

Is Alvotech, through its subsidiaries, (ALVO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $1.52 versus a price of $3.70 — about −59% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALVO?
Our 21-model fair value for Alvotech, through its subsidiaries, is $1.52 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.70.
What is the quality score of ALVO?
Alvotech, through its subsidiaries, has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.